Format

Send to

Choose Destination
Vet J. 2014 Mar;199(3):324-31. doi: 10.1016/j.tvjl.2013.12.013. Epub 2013 Dec 14.

Scopolamine in racing horses: trace identifications associated with dietary or environmental exposure.

Author information

1
1711 Lakefield North Court, Wellington, FL 33414, USA.
2
College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
3
The Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY 40546, USA.
4
The Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY 40546, USA. Electronic address: ttobin@uky.edu.

Abstract

Scopolamine (L-hyoscine) identifications, often in small-number clusters, have been reported worldwide in performance horses over the last 30 years. Scopolamine is an Association of Racing Commissioners International (ARCI) class 3, penalty class B, substance with potential to affect performance. As such, scopolamine identification(s) in race or performance horses can result in significant penalties for the connections of the horse(s). Reviewed here is the worldwide distribution of scopolamine containing plants (primarily Datura spp.), with estimates of their potential toxicity to horses through dietary and/or environmental exposure. Also reviewed are the basic pharmacology of scopolamine and its precursor, urinary concentrations following feedstuff exposure, and the probable pharmacological/forensic significance of such findings. Based on an overview of the world literature on scopolamine, the expected characteristics of inadvertent environmental exposure are also presented with a view to making clear the potential of scopolamine identifications, with or without atropine, as a direct and expected outcome of both the worldwide distribution of scopolamine-containing plants and the sensitivity of modern equine drug testing. It is of particular interest that only 2/30 reported post-event equine identifications of scopolamine have been associated with atropine, suggesting that failure to identify atropine is not a biomarker of pharmaceutical administration of scopolamine. Available quantitative information associated with scopolamine identifications is consistent with the 75 ng/mL regulatory threshold for scopolamine currently used in Louisiana racing in the USA and the 30 ng/mL reporting threshold in effect in European racing.

KEYWORDS:

Atropine; Horses; Penalties; Racing; Scopolamine

PMID:
24440440
DOI:
10.1016/j.tvjl.2013.12.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center